Portfolio Lab

Ligand Pharmaceuticals Inc

  • Stock
  • Ticker LGND
  • ISIN US53220K5048
  • Nasdaq

Health care · Pharmaceuticals · USA

$286.85 −0.03%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Ligand Pharmaceuticals Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

LGNDGlobal equities (VT)

$10,000 grew to $26,731. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −81.9% in 10/2023, measured from the peak in 09/2018. It took 93 months to get back to the old peak.

1-year return
+44.1%
5-year return p.a.
+12.1%
10-year return p.a.
+10.3%
Volatility p.a.
49.5%
Largest decline
−81.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue43454811560526479
Operating income-9.6-368.45515178.6-16
EBITDA-1.0-271764242617-5.4
Net income-31-424.811745-1349-28
Earnings per share-1.68-2.210.245.682.18-0.672.22-1.43
Balance sheet
Total assets9429059491,4771,5611,5322,1862,237
Liabilities1111101205275435351,2181,276
Equity8307968279501,017997968962
Cash7248681391751151,00756
Long-term debt––––––1,127680
Cash flow
Operating cash flow28-251613464924-28
Capital expenditure-0.7-0.2-0.20.00.0-0.20.0-0.1
Free cash flow28-261613464824-28

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +76.5%, weakest 2022 at −56.8%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
30 Oct 2026−$1.43
7 Aug 2026$2.22
8 May 2026−$0.67
27 Feb 2026$2.18
7 Nov 2025$5.68
8 Aug 2025$0.24
9 May 2025−$2.21
28 Feb 2025−$1.68
8 Nov 2024−$0.39
7 Aug 2024−$2.88
8 May 2024$4.75
29 Feb 2024$1.03

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€5.2bn
Market cap in trading currency
$5.74bn
Enterprise value
$6.42bn
P/E
124.7
P/S
22.61
P/B
5.97
EV/Sales
25.29
EV/EBITDA
106.1
Earnings yield
0.8%
FCF yield
1.6%

Results (last four quarters)

Revenue
$254m
Gross profit
–
EBITDA
$60.5m
Net income
$51.5m
Earnings per share
$2.30
Revenue per share
$12.69
Revenue growth
−31.8%
Earnings growth
−124.3%

Profitability

Gross margin
–
Operating margin
10.1%
Net margin
20.3%
Return on equity
5.4%
Return on assets
2.3%

Balance sheet and cash flow

Cash
$447m
Cash per share
$22.37
Financial debt
$1.13bn
Debt/equity %
117
Current ratio
1.22
Book value per share
$48.08
Operating cash flow
$91.0m
Free cash flow
$90.6m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
20.0m
Volume
259,763
Avg. volume 3 months
226,635
Relative volume
1.1

Price and technicals

Price
$286.85
1 day
0.0%
52-week high
$322.75
52-week low
$181.65
Distance to 52-week high
−11.1%
Distance to 52-week low
+57.9%
Distance to 50-day line
−5.1%
Distance to 200-day line
+10.0%
RSI (14)
39
Volatility 1M
39.3%

Performance

1 week
−7.1%
1 month
−6.8%
3 months
+2.4%
6 months
+25.1%
YTD
+51.7%
1 year
+39.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has LGND performed since 11/2016?

$10,000 grew to $26,731 by 20 Nov 2026, which is +10.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is LGND?

Volatility was 49.5% per year, measured on monthly returns. The largest decline from a peak was −81.9%, with the low in 10/2023.

How does LGND compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, LGND returned +10.3% at 49.5%. The correlation of monthly returns was 0.33; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Ligand Pharmaceuticals Inc (LGND): Return and risk